| Christopher N Deyo, MD | |
|
700 West Ave S, La Crosse, WI 54601-4783 | |
| (608) 785-0940 | |
| Not Available |
| Full Name | Christopher N Deyo |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 18 Years |
| Location | 700 West Ave S, La Crosse, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295770014 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LC0200X | Anesthesiology - Critical Care Medicine | 52012 (Wisconsin) | Secondary |
| 207L00000X | Anesthesiology | 52012 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Health System-franciscan Medical Center Inc | La crosse, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic Health System-franciscan Medical Center Inc | 0345152443 | 419 |
News Archive
The current science and experience does not support the safety and efficaciousness of a biosimilar pathway for plasma protein therapies. At a public hearing last week, the Plasma Protein Therapeutics Association (PPTA) urged the United States Food and Drug Administration (FDA) to make patient safety its top priority by adopting a global approach in its evaluation of plasma protein therapies for the biosimilars process.
Australia could be a world leader in medical innovation but commercial risk aversion and parochialism are holding the industry back, a leading venture capitalist will argue at a public lecture and debate at the University of New South Wales next week (Monday, 31 August).
Cell Therapeutics today announced that it has signed a manufacturing agreement with NerPharMa DS (a pharmaceutical manufacturing company belonging to Nerviano Medical Sciences S.r.l. for CTI's drug candidate pixantrone.
Medical students are to receive training in how to become 'culturally competent' as part of the medical curriculum as a consequence of widespread migration across Europe.
The key to immune-based cancer therapies lies in the ability to exploit some weakness within the tumor and its environment or to elude cancer's offenses. Writing in the journal Scientific Reports, researchers led by a group from the Roswell Park Cancer Institute Center for Immunotherapy have shared new insights about a subset of T cells that appear to do both those things, inhibiting cancer growth at the same time that they enhance the tumor-killing powers of other immune cells.
› Verified 9 days ago
| Entity Name | Mayo Clinic Health System-franciscan Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629056049 PECOS PAC ID: 0345152443 Enrollment ID: O20031110000684 |
News Archive
The current science and experience does not support the safety and efficaciousness of a biosimilar pathway for plasma protein therapies. At a public hearing last week, the Plasma Protein Therapeutics Association (PPTA) urged the United States Food and Drug Administration (FDA) to make patient safety its top priority by adopting a global approach in its evaluation of plasma protein therapies for the biosimilars process.
Australia could be a world leader in medical innovation but commercial risk aversion and parochialism are holding the industry back, a leading venture capitalist will argue at a public lecture and debate at the University of New South Wales next week (Monday, 31 August).
Cell Therapeutics today announced that it has signed a manufacturing agreement with NerPharMa DS (a pharmaceutical manufacturing company belonging to Nerviano Medical Sciences S.r.l. for CTI's drug candidate pixantrone.
Medical students are to receive training in how to become 'culturally competent' as part of the medical curriculum as a consequence of widespread migration across Europe.
The key to immune-based cancer therapies lies in the ability to exploit some weakness within the tumor and its environment or to elude cancer's offenses. Writing in the journal Scientific Reports, researchers led by a group from the Roswell Park Cancer Institute Center for Immunotherapy have shared new insights about a subset of T cells that appear to do both those things, inhibiting cancer growth at the same time that they enhance the tumor-killing powers of other immune cells.
› Verified 9 days ago
| Entity Name | Mayo Clinic Health System-franciscan Medical Center Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1841278637 PECOS PAC ID: 0345152443 Enrollment ID: O20100506000523 |
News Archive
The current science and experience does not support the safety and efficaciousness of a biosimilar pathway for plasma protein therapies. At a public hearing last week, the Plasma Protein Therapeutics Association (PPTA) urged the United States Food and Drug Administration (FDA) to make patient safety its top priority by adopting a global approach in its evaluation of plasma protein therapies for the biosimilars process.
Australia could be a world leader in medical innovation but commercial risk aversion and parochialism are holding the industry back, a leading venture capitalist will argue at a public lecture and debate at the University of New South Wales next week (Monday, 31 August).
Cell Therapeutics today announced that it has signed a manufacturing agreement with NerPharMa DS (a pharmaceutical manufacturing company belonging to Nerviano Medical Sciences S.r.l. for CTI's drug candidate pixantrone.
Medical students are to receive training in how to become 'culturally competent' as part of the medical curriculum as a consequence of widespread migration across Europe.
The key to immune-based cancer therapies lies in the ability to exploit some weakness within the tumor and its environment or to elude cancer's offenses. Writing in the journal Scientific Reports, researchers led by a group from the Roswell Park Cancer Institute Center for Immunotherapy have shared new insights about a subset of T cells that appear to do both those things, inhibiting cancer growth at the same time that they enhance the tumor-killing powers of other immune cells.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher N Deyo, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (608) 785-0940 | Christopher N Deyo, MD 700 West Ave S, La Crosse, WI 54601-4783 Ph: (608) 785-0940 |
News Archive
The current science and experience does not support the safety and efficaciousness of a biosimilar pathway for plasma protein therapies. At a public hearing last week, the Plasma Protein Therapeutics Association (PPTA) urged the United States Food and Drug Administration (FDA) to make patient safety its top priority by adopting a global approach in its evaluation of plasma protein therapies for the biosimilars process.
Australia could be a world leader in medical innovation but commercial risk aversion and parochialism are holding the industry back, a leading venture capitalist will argue at a public lecture and debate at the University of New South Wales next week (Monday, 31 August).
Cell Therapeutics today announced that it has signed a manufacturing agreement with NerPharMa DS (a pharmaceutical manufacturing company belonging to Nerviano Medical Sciences S.r.l. for CTI's drug candidate pixantrone.
Medical students are to receive training in how to become 'culturally competent' as part of the medical curriculum as a consequence of widespread migration across Europe.
The key to immune-based cancer therapies lies in the ability to exploit some weakness within the tumor and its environment or to elude cancer's offenses. Writing in the journal Scientific Reports, researchers led by a group from the Roswell Park Cancer Institute Center for Immunotherapy have shared new insights about a subset of T cells that appear to do both those things, inhibiting cancer growth at the same time that they enhance the tumor-killing powers of other immune cells.
› Verified 9 days ago
Jeffrey Brian Trohkimoinen, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, Gundersen Clinic, Ltd., La Crosse, WI 54601 Phone: 608-775-2031 | |
Robert R Groshek, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Kaytie M Curtis, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Richard A Olson, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Joon Yoon, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Dr. Laura Beth Zitelman, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Stephanie Ann Neuman, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 |